We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

PerkinElmer to Acquire UK In-Vitro Diagnostics Company Immunodiagnostic Systems

By LabMedica International staff writers
Posted on 18 May 2021
Print article
Illustration
Illustration
PerkinElmer, Inc. (Waltham, MA; USA) and Immunodiagnostic Systems Holdings PLC (IDS; Boldon, Tyne and Wear, UK) have reached an agreement whereby PerkinElmer will acquire IDS for approximately USD 155 million.

IDS develops, manufactures, and markets innovative immunoassays and automated immunoanalyzer technologies to provide improved diagnostic outcomes for patients. IDS’s immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. PerkinElmer's comprehensive global diagnostics portfolio includes solutions focused on: reproductive health; autoimmune, infectious disease and allergy testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings.

Through this acquisition, PerkinElmer will be able to grow its overall Diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’ best-in-class chemiluminescence products in endocrinology, autoimmunity and infectious diseases to better serve customers around the world. IDS’s portfolio and expertise will seamlessly integrate within EUROIMMUN, a PerkinElmer company since 2017. EUROIMMUN is a global leader in autoimmune testing and an emerging force in infectious disease, allergy and molecular genetic testing.

“This proposed transaction is highly valuable for both parties as the respective product lines are to a large extent complementary,” said Wolfgang Schlumberger, CEO of EUROIMMUN. “The cooperation of our global distribution channels, the expansion of the immunoassay portfolio in closely related indication fields and IDS's fully automated random access chemiluminescence platform strengthens our presence in immunodiagnostics. Our customers will benefit from a broader range of assays and laboratory diagnostic workflows. We are excited about these new opportunities and we look forward to welcoming Immunodiagnostic Systems into the PerkinElmer family following the completion of the transaction.”

Related Links:
PerkinElmer, Inc.
Immunodiagnostic Systems Holdings PLC (IDS)


New
Gold Supplier
SARS-CoV-2 Genome RNA Controls
AMPLIRUN SARS-CoV-2 RNA CONTROL PANEL
New
Silver Supplier
AUTOSAMPLER - CHORUS ACCESSORY
AUTOSAMPLER - CHORUS ACCESSORY
New
SARS-CoV-2 Antibody ELISA Kit
SARS-CoV-2 N-Protein Salivary IgG ELISA Kit
New
Silver Supplier
Sample-to-Result COVID Testing Platform
LabTurbo AIO Sample-to-Result COVID Testing Platform

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.